Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Nov;28(6):e219-e227.
doi: 10.1111/hae.14652. Epub 2022 Aug 22.

Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients

Yaming Xi  1 , Chenghao Jin  2 , Wei Liu  3 , Hu Zhou  4 , Zhen Wang  5 , Rongfu Zhou  6 , Shifeng Lou  7 , Xielan Zhao  8 , Fangping Chen  8 , Peng Cheng  9 , Zimin Sun  10 , Haifei Jia  11 , Lei Zhang  3
Affiliations
Randomized Controlled Trial

Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients

Yaming Xi et al. Haemophilia. 2022 Nov.

Abstract

Introduction: Current treatment of severe haemophilia A includes prophylaxis with factor VIII (FVIII) replacement. The supply of plasma-derived FVIII is short in China.

Purpose: To evaluate the efficacy and safety of a new B-domain deleted (BDD) recombinant FVIII (TQG202) produced by human-derived cells for prophylaxis in severe haemophilia A patients and compare the bioequivalence with Xyntha.

Methods: This multicentre, clinical trial consisted of an open-label, randomized, two-period cross-over trial assessing single-dose pharmacokinetics (PK), and a single-arm clinical trial evaluating the efficacy and safety of 24 weeks of TQG202 prophylaxis, and repeated PK were assessed after prophylaxis phase. The single-dose was 50 IU/kg in PK assessment, and the initial dose was 30 ± 5 IU/kg for prophylaxis. The primary endpoints of prophylaxis were the annualized bleeding rate (ABR) and the incremental recovery rate of the first administration. Adverse events (AEs) were recorded.

Results: Twenty-six participants were enrolled in the PK assessment and 81 participants in the prophylaxis phase. Mean age was 25.9 ± 10.8 years and all participants were male. The results of PK assessment showed TQG202 is bioequivalent to Xyntha. The total ABR was 2.0 (95% CI: 1.2-2.9) in prophylaxis phase. The mean incremental recovery rate of the first administration was .027 (95% CI: .026-.028) (IU/ml)/(IU/kg). AEs occurred in 42 participants, with an incidence of 51.9%. One severe AE not related to TQG202 occurred. No participants developed FVIII inhibitors.

Conclusion: TQG202 shows bioequivalence with Xyntha. The promising efficacy and tolerability in the severe haemophilia A prophylaxis support the use of TQG202in clinical practice.

Keywords: factor VIII, haemophilia A; pharmacokinetics; prophylaxis; recombinant; treatment.

PubMed Disclaimer

Conflict of interest statement

Haifei Jia is employed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. The remaining authors stated that they had no interests which might be perceived as posing a conflict or bias.

Figures

FIGURE 1
FIGURE 1
Participant flowchart
FIGURE 2
FIGURE 2
Plasma concentration‐time curve (A) and average plasma concentration‐time curve (B)
See this image and copyright information in PMC

References

    1. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1‐158. - PubMed
    1. Adam MP, Ardinger HH, Pagon RA, et al. Hemophilia A – GeneReviews®. University of Washington Seattle; 1993.
    1. Rayment R, Chalmers E, Forsyth K, et al. Guidelines on the use of prophylactic factor replacement for children and adults with haemophilia A and B. Br J Haematol. 2020;190(5):684‐695. - PubMed
    1. Berntorp E, Shapiro AD. Modern haemophilia care. Lancet. 2012;379(9824):1447‐1456. - PubMed
    1. Song X, Zhong J, Xue F, et al. An overview of patients with haemophilia A in China: epidemiology, disease severity and treatment strategies. Haemophilia. 2021;27(1):e51‐e59. - PubMed

Publication types